220 related articles for article (PubMed ID: 21336561)
1. Optimal management of bone metastases in prostate cancer.
Aljumaily R; Mathew P
Curr Oncol Rep; 2011 Jun; 13(3):222-30. PubMed ID: 21336561
[TBL] [Abstract][Full Text] [Related]
2. Bone health and prostate cancer.
Saylor PJ; Smith MR
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):20-7. PubMed ID: 19901958
[TBL] [Abstract][Full Text] [Related]
3. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K; Carducci M; Smith M; DamiĆ£o R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
[TBL] [Abstract][Full Text] [Related]
4. Treatment and prevention of bone complications from prostate cancer.
Lee RJ; Saylor PJ; Smith MR
Bone; 2011 Jan; 48(1):88-95. PubMed ID: 20621630
[TBL] [Abstract][Full Text] [Related]
5. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
Smith MR
Urol Oncol; 2008; 26(4):420-5. PubMed ID: 18593621
[TBL] [Abstract][Full Text] [Related]
6. Contemporary management of metastatic castration-resistant prostate cancer.
Sonpavde G; Sternberg CN
Curr Opin Urol; 2011 May; 21(3):241-7. PubMed ID: 21455038
[TBL] [Abstract][Full Text] [Related]
7. Unravelling the role of denosumab in prostate cancer.
Aragon-Ching JB
Lancet; 2011 Mar; 377(9768):785-6. PubMed ID: 21353698
[No Abstract] [Full Text] [Related]
8. A renaissance in the medical treatment of advanced prostate cancer.
Rove KO; Flaig TW
Oncology (Williston Park); 2010 Dec; 24(14):1308-13, 1318. PubMed ID: 21294475
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
Saylor PJ; Lee RJ; Smith MR
J Clin Oncol; 2011 Sep; 29(27):3705-14. PubMed ID: 21860001
[TBL] [Abstract][Full Text] [Related]
10. Novel and bone-targeted agents for CRPC.
Fizazi K; Albiges L; Massard C; Escudier B; Loriot Y
Ann Oncol; 2012 Sep; 23 Suppl 10():x264-7. PubMed ID: 22987974
[TBL] [Abstract][Full Text] [Related]
11. New treatment options for patients with metastatic castration-resistant prostate cancer.
Higano CS
Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
[TBL] [Abstract][Full Text] [Related]
12. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
J Urol; 2009 Aug; 182(2):509-15; discussion 515-6. PubMed ID: 19524963
[TBL] [Abstract][Full Text] [Related]
13. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
14. Management of bone metastases in refractory prostate cancer--role of denosumab.
Paller CJ; Carducci MA; Philips GK
Clin Interv Aging; 2012; 7():363-72. PubMed ID: 23049248
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
Fizazi K; Lipton A; Mariette X; Body JJ; Rahim Y; Gralow JR; Gao G; Wu L; Sohn W; Jun S
J Clin Oncol; 2009 Apr; 27(10):1564-71. PubMed ID: 19237632
[TBL] [Abstract][Full Text] [Related]
16. Contemporary therapeutic approaches targeting bone complications in prostate cancer.
Lee RJ; Saylor PJ; Smith MR
Clin Genitourin Cancer; 2010 Dec; 8(1):29-36. PubMed ID: 21208853
[TBL] [Abstract][Full Text] [Related]
17. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
[TBL] [Abstract][Full Text] [Related]
18. Novel therapies for metastatic castrate-resistant prostate cancer.
Dayyani F; Gallick GE; Logothetis CJ; Corn PG
J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
[TBL] [Abstract][Full Text] [Related]
19. Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
Aapro M; Saad F; Costa L
Oncologist; 2010; 15(11):1147-58. PubMed ID: 21051658
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer bone metastases: denosumab or zoledronic acid?
van der Pluijm G
Nat Rev Endocrinol; 2011 Mar; 7(3):134-5. PubMed ID: 21343953
[No Abstract] [Full Text] [Related]
[Next] [New Search]